Very informative CC, The revenue guidance was a little vague but the market potential of 150 mil was reassuring. Humble estimates would put us earning 25 mil next year till Lympro becomes the go to test with BD. If the LP-002 study comes back with a solid SPECs number we may take even more of the market.

With all of the positives that we received from the CC call, I still can not justify voting yes for additional shares. To many unknowns are still in the balance.